<?xml version="1.0" encoding="UTF-8"?>
<p class="p">At T0, the two groups showed no significant differences in mean of FMPS values, full-mouth PD and CAL. At T1, the TG group showed a significant decrease in FMPS (
 <italic class="italic">p</italic> = 0.005) compared with the CG group. Moreover, there were no significant differences in mean of full-mouth PD and CAL between the two groups at T1: both groups showed a significant reduction in PD (
 <italic class="italic">p</italic> = 0.001 TG; 
 <italic class="italic">p</italic> = 0.011 CG) and CAL (
 <italic class="italic">p</italic> &lt; 0.001 TG; 
 <italic class="italic">p</italic> = 0.020 CG) values from baseline to 3 months (
 <xref rid="T2" ref-type="table" class="xref">Table 2</xref>). There were no subjective complaints, adverse outcomes or side effects reported or observed in both groups at day 20, 40, 60, 80 and 3 months (
 <xref rid="T3" ref-type="table" class="xref">Table 3</xref>).
</p>
